West Pharmaceutical Services, Inc.
WST · Price history
Price at last available close
$398.29
+$22.64 (+6.03%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About West Pharmaceutical Services, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements.
How they make money
West Pharmaceutical Services designs and manufactures proprietary packaging, containment solutions, and drug delivery systems for injectable medicines. The company also operates a contract-manufacturing business that provides design, development, and automated assembly services for complex medical devices and diagnostic products used by pharmaceutical and healthcare companies.
Products & services
Injectable drug packaging, elastomers, primary containment solutions, drug delivery devices, integrated systems, analytical lab services, and contract-manufactured medical and diagnostic devices.
Brands & revenue mix
Integrated service platform for the design, development, and manufacture of drug-delivery devices.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
The ten largest customers accounted for 47.6% of consolidated net sales in 2025, with one individual customer accounting for 15.8% ($485.9 million) of consolidated net sales.
Suppliers, materials & equipment
- Raw material suppliers — The company relies on various suppliers for raw materials and components; specific supplier names are not disclosed.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
43
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
76
Strong
Financial Strength
62
Business Quality / Moat
77
Management
100
Growth Quality
54
Risk / Durability
98
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
30
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
38/100
Building Historical Record
Model Score 38/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •M&A headline · Aug 22, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for WST
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can WST maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is WST's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does WST's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What future growth or profitability would be needed to justify WST's current valuation?
Essential Investment Snapshot
Wall Street Score
43
Opportunity Score
30
Market Cap
$28.03B
P/E Ratio
50.0
EPS
$7.87
52-Week High
$397.16
52-Week Low
$223.83
Beta
1.13
Intrinsic Value
$100.40
Analyst Target
$420.00
Shares Outstanding
72.7M
Total Revenue
$3.33B
Total Debt
$312.1M
Dividend Yield (TTM)
0.22%
Liquidation Value / Share
$41.13
Dividend / Share (TTM)
$0.88
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for WST
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Aug 22, 2026
Advisors Capital Management LLC Acquires New Shares in West Pharmaceutical Services, Inc. $WST — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on WST.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary technology and integrated service offerings.
- +Strong market position in injectable drug containment.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
- −Customer concentration and reliance on major pharmaceutical accounts.
- −Regulatory compliance and quality standards requirements.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
43
Oct 23, 2026
Change
Unchanged
Current Score
43
Oct 26, 2026
Category Changes
WST score was unchanged.
Projected Score
Projected Score
43
Projected Change
+0.4 points
Preliminary comparable-period financial changes suggest improvement of approximately 0.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$398.29
Model Intrinsic Value
$100.40
Difference
+$297.89
+296.7% vs IV
Margin of Safety
-296.7%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.33B | $3.07B | $2.89B | $2.95B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $2.10B | $1.97B | $1.89B | $1.82B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $1.22B | $1.10B | $1.00B | $1.13B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $74.4M | $74.3M | $69.1M | $68.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $426.3M | $393.1M | $338.5M | $353.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $536.0M | $485.9M | $407.6M | $421.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $870.4M | $770.6M | $743.8M | $844.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $686.5M | $617.4M | $594.6M | $710.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $100K | $600K | $2.9M | $8.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $699.6M | $615.3M | $600.2M | $715.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $144.2M | $121.6M | $107.5M | $122.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $564.9M | $493.7M | $492.7M | $593.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $7.87 | $6.83 | $6.75 | $7.99 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 70.80M | 72.30M | 73.00M | 74.30M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 71.30M | 72.70M | 73.70M | 75.30M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$872.3M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$2.15
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+2.9%
Cash Change
-14.5%
Margin Change
+0.5 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
What Weakened
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, net income margin. Pressure indicators included cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 13.8%. EPS increased 18.1%. Cash declined 14.5%. Total debt increased 2.9%. Net income margin improved by 0.5 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
32
Smart Money
32
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness?
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Declares Quarterly Dividend
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
Rumor Mill · WST
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial